Qiagen (NASDAQ: QGEN) reported Q1 EPS of $0.22, in-line with the analyst estimate of $0.22. Revenue for the quarter came in at $298.7 million versus the consensus estimate of $304.6 million.

2015 outlook

QIAGEN reaffirms its expectations to deliver higher CER adjusted net sales and adjusted earnings in 2015, as above-market sales growth from the current core portfolio - led by the growth drivers - well exceeds the final year of significant headwinds from reduced U.S. sales of HPV products. These expectations do not take into account any further acquisitions that could be completed in 2015.

For the full year, adjusted net sales are expected to rise approximately 4% CER in 2015, as growth of about 7-8% CER in the core portfolio (including contributions from the Enzymatics acquisition in late December 2014) exceeds the adverse impact of approximately 3-4 percentage points from lower U.S. HPV sales. Adjusted diluted earnings per share (EPS) are expected to be approximately $1.16-1.18 CER compared to $1.00 in 2014. Based on current exchange rates, QIAGEN expects the movements of the U.S. dollar, its reporting currency, against various currencies to have an adverse impact on full-year adjusted sales and EPS results.

For the second quarter of 2015, adjusted net sales are expected to rise approximately 4% CER, which includes approximately 4-5 percentage points of headwind from lower sales of HPV products in the U.S. compared to the same period in 2014, and adjusted EPS of approximately $0.26-0.27 CER. Based on exchange rates as of April 30, 2015, QIAGEN expects currency movements to have an adverse impact of approximately 10 percentage points on reported sales growth and approximately $0.02 per share on adjusted EPS in the quarter.

"Our results for the first quarter of 2015 show QIAGEN continues to deliver a solid performance while moving ahead on our transformation and preparations for a new growth wave. We are building momentum through our portfolio of growth drivers, which represent about 30% of sales and are expanding at a double-digit pace as we invest in new products and key markets. During the first quarter, QIAGEN further advanced its leadership in the rapidly emerging market for liquid biopsies, using non-invasive blood tests to obtain valuable molecular insights. The launches of the fourth-generation QuantiFERON-TB Gold Plus test to support the fight on tuberculosis and the QuantiFERON Monitor test to address a large unmet need for monitoring immune function in transplant patients are building momentum. Sales of HPV test products in the U.S. continue to decline due to pricing pressure, but it now represents only 4% of total sales, and we expect 2015 to be the final year of significant challenges. We are reaffirming our goals for higher adjusted sales and earnings at constant exchange rates in 2015 as we move forward on our strategic ambitions to offer Sample to Insight solutions to our customers," said Peer M. Schatz, Chief Executive Officer of QIAGEN N.V.

For earnings history and earnings-related data on Qiagen (QGEN) click here.